Notes
alogliptin, exenatide, linagliptin, sitagliptin, saxagliptin
References
Egan AG, et al. Pancreatic Safety of Incretin-Based Drugs -- FDA and EMA Assessment. New England Journal of Medicine 370: 794-797, No. 9, 27 Feb 2014. Available from: URL: http://doi.org/10.1056/NEJMp1314078.
Rights and permissions
About this article
Cite this article
Incretin-based therapies linked to pancreatic cancer?. Reactions Weekly 1626, 5 (2016). https://doi.org/10.1007/s40278-016-22586-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-016-22586-x